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Introduction {#sec1-1}
============

Oxalate is a toxic compound ubiquitous in the plant kingdom and widely consumed in normal human diets as a component of fruits, vegetables, grains and nuts (Hodgkinson, [@ref12]). The normal daily intake of oxalate ranges from 70 to 920 mg, but strongly increases in vegetarians (Turroni *et al.*, [@ref24]). Oxalic acid is a highly oxidized organic compound and is a strong chelator of cations, especially Ca^2+^. These properties result in limited possibilities for its catabolism and also make oxalate toxic, especially for mammalians. The accumulation of oxalic acid may lead to several pathologic conditions, including hyperoxaluria, urolithiasis, renal failure, cardiomyopathy and cardiac conductance disorders (Turroni *et al.*, [@ref24]).

The current therapeutic drug treatment options for primary hyperoxaluria and/or the dietetic regimen for patients with secondary hyperoxaluria do not always lead to adequate success, e.g. sufficient reduction of urinary oxalate excretion. Hence, new treatment options are clearly needed. In addition, an oxalate-free diet is difficult to achieve and would probably be deficient in essential micronutrients. The discovery of oxalate-degrading bacteria in the human gastro intestinal tract has opened the way to several investigations regarding their potential role in reducing the urinary excretion of oxalic acid (Giardina *et al.*, [@ref9]). Treatment with oxalate degrading bacteria could be such a new therapeutic option in patients with both form of hyperoxaluria. The most studied oxalate-degrading bacterium is *Oxalobacter (O.) formigenes*, a Gram-negative strictly anaerobic bacterium, found in the colon of humans and other vertebrates (Weese *et al.*, [@ref25]). The pathway for oxalate utilization in *O. formigenes* involves two enzymes: formyl-CoA transferase and oxalyl-CoA decarboxylase (Turroni *et al.*, [@ref24]) responsible for the conversion in CO~2~ and formate further metabolized and excreted via faeces. Treatments with *O. formigenes* have been proposed for patients with either absorptive and/or dietary, hence secondary, hyperoxaluria: colon recolonization by *O. formigenes* may lead to up a 50% reduction of urinary oxalate excretion (Hatch *et al.*, [@ref11]; Jiang *et al.*, [@ref16]).

Apart from *O. formigenes*, strains within *Bifidobacterium* and *Lactobacillus (Lb.)* genera are known to efficiently metabolize oxalate in dogs (Gnanandarajah *et al.*, [@ref10]). As matter of fact, several surveys were focused on the search of oxalates degradation abilities in Lactic acid Bacteria (LAB) strains (Hokama *et al.*, [@ref13]; Hoppe *et al.*, [@ref14]; Lieske *et al.*, [@ref19]; Turroni *et al.*, [@ref24]; Murphy *et al.*, [@ref20]; Ren *et al.*, [@ref21]). Anbazhagan *et al.* ([@ref3]) generated a recombinant *Lb. plantarum* strain able to efficiently degrade oxalate up to 90%, against a 15% of not modified bacteria. Since the use of genetically modified organisms is not allowed, a search for oxalate degrading activities within LAB of food origin was attempted.

Materials and methods {#sec1-2}
=====================

Seventy-nine LAB strains were dropinoculated onto MRS (Oxoid, Basingstoke, UK) agar plates containing 50 mmol/L of calcium oxalate. After incubation at 30°C for 48 hours, the presence of clear areas around to bacterial colonies was considered indication of oxalate degradation.

Selected strains were tested for sodium oxalate degradation in MRS broth containing 20 mmol/L of sodium oxalate (MRS-ox) as described by Ren *et al.* ([@ref21]). Isolates were cultured twice in MRS and then used to inoculate in parallel MRS and MRS-ox broth. After incubation at 37°C for 72 h, bacterial loads were assessed by drop counts on MRS agar. After centrifugation at 12,000 rpm for 15 min, supernatants were examined by high performance liquid chromatography (HPLC) according to Blaiotta *et al.* ([@ref6]). Analysis was performed on samples diluted in mobile phase 1:5 (vol/vol) and filtered by AcroDisc millipore (0.2 μm) by system (Gilson 307 Series HPLC system; Gilson, Middleton, WI, USA) fitted with column (MetCarb68 Hcolumn 6.5×300 mm, Varian) in an oven thermostated at 65°C. Columns were eluted at 0.4 mL/min by a solution 0.25 N H~2~SO~4~ in ultrapure water. A refractometer (RID 133, Gilson) was used as detector. Standards were used for quantification of different sugars and acids in the samples. Each experiment was performed in triplicate. For two strains, trials were repeated with MRS-ox broths with different glucose concentrations (0, 5 or 10 g/L). After 6, 24, 30, 48, 54 and 72 hours of incubation at 37°C, the bacterial populations were quantified by MRS counts and O.D. determination, while oxalate concentrations were assessed by HPLC.

Results {#sec1-3}
=======

MRS agar containing calcium oxalate did not allow a clear discrimination of oxalate-degrading stains. All 79 LAB cultures grew on the agar plates and in no case the development of a clear halo surrounding colonies was evident (data not shown). By comparing the diameter of the colonies, 31 strains were selected ([Table 1](#table001){ref-type="table"}). Cultures were used to inoculate, in parallel, MRS-ox, namely MRS modified by sodium oxalate addition, and unmodified MRS. CFU counts were used to compare strains. Around 68% of the strains presented an higher growth in MRS broth base than in MRS-ox, but such difference proved to be significant (P\<0.05) for 11 strains *(Enterococcus* spp. 11, 16, 26 and 59, *Ec. durans* 17, *Ec. faecalis* 62, *Lb. johnsonii* La1, *St. thermophilus* DSM8713 and DSM20617, *Lb. reuteri* Bio and *Lb. casei* Lbc496). Similarly, 11 strains showed a better growth in MRS-ox, but the difference was significant for just two strains: *Lb. rhamnosus* LbGG and *St. salivarius* DSM20479 ([Table 1](#table001){ref-type="table"}).

Strains LbGG, DSM 20479 and RBT739, all characterized by a better growth in presence of oxalate and *Ec. faecalis* 59, showing an opposite behaviour were selected for further experiments. CFU counts confirmed previous outcomes, while the oxalate degradation, as revealed by HPLC analyses proved to be more efficient in strain LbGG rather than in RBT739 ([Figure 1](#fig001){ref-type="fig"}). Strain 59 showed a reduced consumption of sugar, followed by a lower production of lactic acid. The influence of the glucose on the utilization of sodium oxalate was evaluated by repeating the same set of trials in MRS-ox with decreasing glucose concentrations, namely half content (5 g/L) and without (0 g/L) glucose ([Figure 2](#fig002){ref-type="fig"}). The presence of glucose seemed to exert a substantial effect on the oxalate consumption, since in broth without glucose, oxalate consumption was similar for both strains ([Figure 2](#fig002){ref-type="fig"}).

The analysis in MRS-ox with different glucose concentration was then repeated, by monitoring strains along incubation up to 72 hours ([Figure 3](#fig003){ref-type="fig"}). Cultures turbidity showed the same trend in the broth culture with 5 and 10 g/L of glucose, with a higher level of turbidity in broth cultures with the highest glucose concentration (data not shown). LbGG showed an humble growth in broth without glucose as revealed by CFU counts and pH monitoring ([Figure 3](#fig003){ref-type="fig"}). The cells number increased after the first 24 hours of incubation, afterward lactobacilli loads started to drop. Actually, populations decline in MRS without glucose started at 24 hour, while in the media with sugar, the drop begins after 48 hours. The increase of LAB populations was of almost one log for trials glucose-added. pH trends confirmed LAB counts evolution. HPLC analysis revealed an higher lactic acid production as long as the concentration of glucose increases. On the other hand, the acid acetic production registered a fluctuating trend along time.

The chromatographic analysis confirmed a higher oxalate consumption in presence of the maximum glucose concentration. Citric acid was fully metabolized in the medium without glucose and its consumption decreased with the increase of glucose concentration.

Discussion {#sec1-4}
==========

In the present study, a screening for oxalates degrading activity was carried out by considering 79 LAB strains known for probiotic features or isolated from foods and evaluated for functional capabilities during previous surveys (Aponte *et al.*, [@ref5], [@ref4]; Blaiotta *et al.*, [@ref6]; Ricciardi *et al.*, [@ref22]). Strains exhibiting a better growth on MRS agar plates enriched in oxalates were further investigated. According to outcomes, most of the strains showed a low oxalate degrading capacity. Among the tested strains, *Lb. rhamnosus* GG exhibited the highest percentage of oxalate consumption, above all in the presence of glucose. To authors' knowledge, this is the first time that this popular probiotic strain has been investigated for such feature. Results even proved a correlation between the presence of sugars and the rate of oxalate consumption, thus underlining that the availability of glucose might provide an input for the oxalate metabolism as already pointed out by Ren *et al.* ([@ref21]). Without glucose, both LbGG and *Ec. faecalis* 59, isolated from Pecorino di Carmasciano cheese (Ricciardi *et al.*, [@ref22]) fully metabolized citrate and, above all, utilized oxalate at the same level. In other words, LbGG proved to degrade less efficiently the salt, while *Ec. faecalis*, that was chosen for its inability to degrade oxalate, exhibited an attitude comparable to that recorded for LbGG.

Conclusions {#sec1-5}
===========

Many reports are currently focused on oxalates degrading capacity of O. *Formigenes* (Knight *et al.*, [@ref18]). However, its safety issue and health benefits are not as well established as in LAB. The research of different microorganisms able to express the same degrading-capacities led to investigate on several LAB strains mainly referable to *Enterococcus* spp and *Lactobacillus* spp (Hokama *et al.*, [@ref13]; Turroni *et al.*, [@ref24]). *Bifidobacterium* and *Lactobacillus* strains are commonly used in dairy and pharmaceutical probiotic preparation and are generally recognised as safe for human consumption (Fao, [@ref8]; Iqbal *et al.*, [@ref15]). However, all studies highlighted in LAB cultures a minor oxalate degrading capacity if compared *O. formigenes* performances, for two main reasons: LAB prefer other substrates to obtain energy (Ren *et al.*, [@ref21]), and the genes encoding for the synthesis of oxalate degrading enzymes are less efficient than those reported in *O. formigenes* (Turroni *et al.*, [@ref24]). Basing on outcomes obtained in the present survey, *Lb. rhamnosus* GG, never evaluated before for this feature, may express an interesting potential for the degradation of oxalate. Since LbGG is well known for its ability to survive and to tolerate adverse storage conditions in dairy products (Alampreese *et al.*, [@ref1]), fresh-cut apple (Alegre *et al.*, [@ref2]), maple sap (Khalf *et al.*, [@ref17]), chestnut purees and mousses (Blaiotta *et al.*, [@ref6]; Romano *et al.*, [@ref23]), and emmer beverages (Coda *et al.*, [@ref7]), new perspectives may be hypothetised for the production of probiotic food, with particular emphasis on fermented vegetable foods, with reduced oxalates content and endowed with LbGG, thus likely to promote an oxalate reduction in the human organism, beyond the beneficial and therapeutic effects commonly associated to the ingestion of such probiotic strain.

![Oxalate degrading ability of *Lb. rhamnosus* strains LbGG and RBT739, *St. salivarius* DSM 20479, and *Ec. faecalis* 59 after 24 h of incubation. Evolution of reducing sugars, organic acids by high performance liquid chromatography and of microbial loads in MRS and MRS-added of sodium oxalate are reported. Un-inoculated broth served as control.](ijfs-6-2-6345-g001){#fig001}

![Oxalate degrading ability of *Lb. rhamnosus* LbGG and *E. faecalis* 59 in MRSadded of sodium oxalate with decreasing glucose concentrations (10, 5, 0 g/L). Content of glucose, lactic, acetic and citric acids by high performance liquid chromatography are reported. Un-inoculated broth served as control.](ijfs-6-2-6345-g002){#fig002}

![Evolution of pH (continuous lines) and MRS counts (dashed lines) (A); glucose (continuous lines) and lactic acid (dashed lines) (B); oxalic, citric and acetic acids (C) of *Lb. rhamnosus* GG in in MRS-added of sodium oxalate with decreasing glucose concentrations (10, 5, 0 g/L) during 72 h of incubation.](ijfs-6-2-6345-g003){#fig003}

###### 

Growth in MRS and MRS-added of sodium oxalate of strains used in this study.

  Strain                                      Source                                                                               Taxon                 CFU/mL      
  ------------------------------------------- ------------------------------------------------------------------------------------ --------------------- ----------- -----------
  8                                           Ricciardi *et al.* ([@ref22])                                                        *Ec. hirae*           7.85±0.08   7.54±0.16
  11                                          Ricciardi *et al.* ([@ref22])                                                        *Enterococcus* spp.   7.56±0.17   6.46±0.14
  15                                          Ricciardi *et al.* ([@ref22])                                                        *Ec. durans*          8.00±0.10   8.07±0.15
  16                                          Ricciardi *et al.* ([@ref22])                                                        *Enterococcus* spp.   8.28±0.17   7.07±0.19
  17                                          Ricciardi *et al.* ([@ref22])                                                        *Ec. durans*          7.78±0.18   6.53±0.13
  24                                          Ricciardi *et al.* ([@ref22])                                                        *Ec. hirae*           8.65±0.12   8.52±0.11
  26                                          Ricciardi *et al.* ([@ref22])                                                        *Enterococcus* spp.   8.43±0.12   6.54±0.17
  30                                          Ricciardi *et al.* ([@ref22])                                                        *Enterococcus* spp.   6.46±0.08   6.96±0.17
  31                                          Ricciardi *et al.* ([@ref22])                                                        *Ec. durans*          7.63±0.08   7.24±0.10
  35                                          Ricciardi *et al.* ([@ref22])                                                        *Ec. hirae*           8.70±0.16   8.30±0.16
  36                                          Ricciardi *et al.* ([@ref22])                                                        *Enterococcus* spp.   8.35±0.11   8.40±0.12
  51                                          Ricciardi *et al.* ([@ref22])                                                        *Enterococcus* spp.   8.24±0.19   8.65±0.17
  59                                          Ricciardi *et al.* ([@ref22])                                                        *Enterococcus* spp.   8.77±0.19   6.76±0.13
  61                                          Ricciardi *et al.* ([@ref22])                                                        *Enterococcus* spp.   8.10±0.18   7.48±0.17
  62                                          Ricciardi *et al.* ([@ref22])                                                        *Ec. faecalis*        8.10±0.13   7.00±0.14
  La1                                         Nestlé, Vevey, Switzerland                                                           *Lb. johnsonii*       8.28±0.17   7.18±0.14
  YIT9029                                     Yakult Honsha Co. Ltd., Tokyo, Japan                                                 *Lb. casei* Shirota   8.26±0.20   8.75±0.18
  DN-114 001                                  Danone, Paris, France                                                                *Lb. casei*           8.50±0.21   8.86±0.12
  DSM20479                                    Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany   *St. salivarius*      7.26±0.20   8.57±0.16
  DSM8713                                     Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany   *St. thermophilus*    8.03±0.17   6.50±0.16
  DSM20617                                    Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany   *St. thermophilus*    8.45±0.19   7.38±0.23
  LbGG                                        Blaiotta *et al.* ([@ref6])                                                          *Lb. rhamnosus*       7.77±0.21   8.53±0.24
  VT1                                         Blaiotta *et al.* ([@ref6])                                                          *Lb. rhamnosus*       8.69±0.18   8.88±0.23
  RBT739                                      Blaiotta *et al.* ([@ref6])                                                          *Lb. rhamnosus*       8.38±0.14   8.83±0.15
  RBM526                                      Blaiotta *et al.* ([@ref6])                                                          *Lb. rhamnosus*       7.84±0.10   7.83±0.14
  OM13                                        Aponte *et al.* ([@ref4])                                                            *Lb. pentosus*        7.78±0.16   7.77±0.20
  Lbc491                                      Aponte *et al.* ([@ref5])                                                            *Lb. casei*           7.50±0.17   7.60±0.19
  Lbc496                                      Aponte *et al.* ([@ref5])                                                            *Lb. casei*           8.46±0.19   7.58±0.13
  Bio                                         BioGaia AB, Stockholm, Sweden                                                        *Lb. reuteri*         7.22±0.14   5.26±0.20
  ATCC393                                     American Type Culture Collection                                                     *Lb. casei*           8.12±0.21   8.03±0.15
  Lyofast LC4P1 Sacco, Cadorago (CO), Italy   *Lb. casei*                                                                          8.68±0.23             8.28±0.13   

CFU, colony forming units; MRS-ox, MRS-added of sodium oxalate. Strains code, species identity and source are reported.
